CareCost Prior authorization
Required
Check what the payer requires before you schedule Injectafer.
16 payers, 181 rules, and 11 of them make you fail another IV iron first.
16 payer policy sets hold a ferric carboxymaltose policy · source-linked · reviewed August 2026
Aetna + iron-deficiency anemia with oral iron failure is shown as a live example until you choose a payer.
This payer requires an approval on file before Injectafer is purchased or administered for this member.
Precertification of Feraheme, Ferrlecit, Injectafer, Monoferric, and Venofer are required of all Aetna participating providers and members in applicable plan designs
Covered under ICD-10 D50.
Treatment of members 1 year of age and older who have documented iron deficiency anemia with an unsatisfactory response, intolerance or contraindication to oral iron administration
What opens in CareCost
Aetna · Injectafer · IDA, oral iron failed or not tolerated
For every requirement: the exact payer criteria, the source citation, a check-off, and a save to the patient’s chart.
In CareCost: check off each requirement · save to the patient · print for the chart
Aetna · Injectafer · IDA, oral iron failed or not tolerated
You have already checked the policy, indication and covered dose. Open the remaining requirements and work them as a patient checklist.
CareCost tracks Injectafer coverage requirements across 16 payer policy sets.
Aetna · Anthem / Elevance · Cigna · UnitedHealthcare · BCBS Kansas · Capital BlueCross · BCBS plans + more
Coverage clearance is only the first step.
CareCost carries the same patient through the entire workflow.
Finish this patient’s estimate →14 of 16 commercial payers with a ferric carboxymaltose policy require prior authorization. Clinical criteria, diagnosis coding and dosing limits vary by plan. CareCost has not found a payer in this corpus that carries no ferric carboxymaltose policy at all — every payer checked has one.
14 require PA · 14 have clinical criteria · 2 restrict site of care · 2 list contraindication exclusions
14 of the 16 payers CareCost has read require an approval on file before ferric carboxymaltose is covered. Excellus BCBS ties it to the line of business directly: “Prior Authorization applies to new starts and existing users for the Commercial, Essential, Exchange, Child Health Plus, and Medicaid/HARP lines of business.” Aetna’s precertification rule is class-wide rather than Injectafer-specific: “Precertification of Feraheme, Ferrlecit, Injectafer, Monoferric, and Venofer are required of all Aetna participating providers and members in applicable plan designs.” Two payers — Arkansas BCBS and Independence Blue Cross — carry no formal prior-authorization rule for ferric carboxymaltose in this corpus; Independence still reviews the same clinical criteria before it pays.
15 of the 16 payers write oral-iron failure or intolerance into a rule, and it is where a prior authorization is refused most often. BCBS Kansas requires “an intolerance or inadequate response to a minimum of 14 days of oral iron.” Anthem requires “a four (4) week trial of and inadequate response, or intolerance to oral iron supplementation.” Capital BlueCross: the patient “had an intolerance or inadequate response to a minimum of 14 days of oral iron.” This is a trial of the oral drug class, applied before any injectable iron — Injectafer included — is considered.
Clear the oral-iron gate and 11 of the 16 payers still require a documented failure of another IV iron before Injectafer specifically is paid. Ten of them name specific products or say “generic IV iron” outright; the eleventh, Anthem, applies a formulary step instead. Two payers — UnitedHealthcare and Independence Blue Cross — want failure on two products, not one.
Wellmark BCBS lists Injectafer behind its own preferred group: “The preferred products Feraheme, Ferrlecit, Infed, and Venofer are considered medically necessary…” with Injectafer covered only as the non-preferred exception. UnitedHealthcare requires “laboratory values demonstrating treatment failure to at least two of the following intravenous iron therapies.” Independence requires “documentation of a contraindication, intolerance (e.g., as documented per the FDA labeling), or inadequate response to TWO OR MORE” of the plan’s preferred products (ferumoxytol, ferric derisomaltose) — but only for the IDA and non-dialysis CKD indications; Independence’s heart-failure indication carries no such rule.
Centene requires failure of “Ferrlecit and iron sucrose (generic Venofer)” for the CKD indication, and “two of the following… Ferrlecit, Infed, or iron sucrose (generic Venofer)” for the default oral-intolerance indication. Florida Blue requires a three-week trial of one of iron dextran (INFeD, Dexferrum), iron sucrose (Venofer) or sodium ferric gluconate complex, evidenced by labs. Excellus requires “a medical reason why Feraheme (ferumoxytol) cannot be used.”
Premera requires an inadequate response to “at least 1 of the following preferred IV iron products:” Ferrlecit (sodium ferric gluconate complex), generic sodium ferric gluconate complex, INFeD (iron dextran) or Venofer (iron sucrose). Cigna’s non-dialysis CKD indication accepts a documented trial of “at least one of the following” — INFeD, sodium ferric gluconate complex (Ferrlecit, generics) or Venofer — as one of three qualifying paths. Aetna requires “a contraindication, intolerance or ineffective response to the available equivalent alternative intravenous iron products.”
Blue Shield of California requires “inadequate response or intolerable side effect to preferred generic IV iron products” on the IDA and CKD indications, and to “all generic IV iron products” for heart failure. Anthem requires “a trial and inadequate response or intolerance to two (2) preferred agents” — a class-wide formulary step, applied across every indication, that does not name specific products but still leaves Injectafer non-preferred.
The other 5 payers — Arkansas BCBS, BCBS Kansas, BCBS Minnesota, BCBS South Carolina and Capital BlueCross — gate on oral iron and lab thresholds only, with no named IV-iron alternative and no formulary step in the rule.
10 of the 16 payers name a ferritin threshold and 7 name a transferrin saturation (TSAT) threshold. BCBS Kansas: “ferritin ≤100 ng/mL OR ferritin ≤300 ng/mL when transferrin saturation (TSAT) ≤30%.” Independence Blue Cross sets a lower bar for the oral-iron-failure indication: “ferritin level <30 ng/mL OR transferrin saturation (TSAT) <20%.” Excellus BCBS: “serum ferritin < 30 ng/mL.” No payer in this corpus asks for a serum phosphate level — the label’s boxed warning requires a phosphate check before a repeat course within three months, but that is a prescribing safeguard, not a coverage condition.
BCBS Kansas, BCBS Minnesota and Capital BlueCross cap J1439 at 1,500 units per 35 days; Aetna and Excellus at 1,000 mg per dose. BCBS Kansas’s limit reads “1500 billable units per 35 days,” matched by BCBS Minnesota and Capital BlueCross. Aetna and Excellus instead cap the single-dose alternative: Aetna’s limit reads “Injectafer 15 mg/kg body weight up to a maximum of 1,000 mg,” and Excellus caps the same alternative at “a maximum of 1,000 mg IV… administered as a single-dose per course.” Anthem sets its own limit at “1500 mg per 7 days.”
BCBS Kansas and Capital BlueCross renew heart-failure authorizations in 12-week blocks, up to three maintenance doses. BCBS Kansas: “Prior authorization validity may be renewed every 12 weeks (for 1 dose) up to a total of 3 maintenance doses.” Capital BlueCross matches it: coverage runs “for 12 weeks (for up to 2 doses) initially and may be renewed every 12 weeks (for 1 dose) up to a total of 3 maintenance doses.” UnitedHealthcare caps both the initial and continuation authorization at 12 months: “Continuation authorization will be for no longer than 12 months.” Florida Blue’s approval duration is shorter across the board: “Approval duration: 6 months.”
2 of the 16 payers carry site-of-care language, and both apply it to the whole IV-iron class rather than to Injectafer alone. Independence Blue Cross: the plan will “reimburse only those services that are furnished in the most appropriate and cost-effective setting,” a class-wide reservation covering every IV iron product, including ferric carboxymaltose. Excellus BCBS: “the requested site of care may impact approval timeframe and subject to review.”
Injectafer shares its clinical territory with five other billable IV-iron products — Venofer (J1756), Monoferric (J1437), Feraheme (Q0138), Ferrlecit (J2916) and INFeD (J1750). The price spread between them is part of what shows up as a step requirement at 11 of the 16 payers in this corpus.
| Product | Code | Per 1,000 mg of iron (Q4 2026) |
|---|---|---|
| Ferrlecit | J2916 | $156.48 |
| Venofer | J1756 | $224.00 |
| Feraheme | Q0138 | $331.00 |
| INFeD | J1750 | $380.10 |
| Injectafer | J1439 | $1,121.00 |
| Monoferric | J1437 | $2,187.70 |
Injectafer is 5× Venofer for the iron itself. 10 of the 16 payers in this corpus name a specific product from this table, or “generic IV iron” outright, that the patient must fail first. Two of those ten — UnitedHealthcare and Independence Blue Cross — require failure on two products, not one.
Anthem is the eleventh payer with a step, but it is a formulary rule, not a named-product one: “a trial and inadequate response or intolerance to two (2) preferred agents,” applied class-wide. The other 5 payers — Arkansas BCBS, BCBS Kansas, BCBS Minnesota, BCBS South Carolina and Capital BlueCross — do not name any product or formulary step; they gate on oral iron and lab thresholds only.
Every payer in this corpus that covers ferric carboxymaltose still requires oral-iron failure and the diagnosis codes below regardless — the second gate is layered on top of that one, not a replacement for it.
Iron-deficiency anemia and heart failure both carry parent ICD-10 categories that require a fourth character to be billable. A claim coded to a bare category alone will be rejected.
| Indication | ICD-10 | Notes |
|---|---|---|
| Iron-deficiency anemia, oral iron failed or not tolerated | D50.9 | Reference code used by this site |
| Iron-deficiency anemia, other/unspecified etiology | D50.0 / D50.8 | Also billable; the bare D50 is a category code and is not |
| Iron-deficiency anemia in non-dialysis CKD | D63.1 | Pairs with a CKD staging code, N18.30–N18.5 |
| Iron deficiency in heart failure (NYHA II/III) | E61.1 | Primary code for the heart-failure indication |
| Heart failure, billable pair for E61.1 | I50.20–I50.23, I50.30–I50.33, I50.40–I50.43, I50.9 | The bare I50.2, I50.3 and I50.4 category codes are not billable |
Verified against the NLM Clinical Table Search Service on 2026-09-19.
CareCost’s own Injectafer Medicare coverage page confirms there is no drug-specific National Coverage Determination, Local Coverage Determination or Billing & Coding Article for J1439 in the CMS Medicare Coverage Database. Coverage under Part B is judged per medical necessity by your Medicare Administrative Contractor (MAC), using the FDA-approved indications as the starting point.
This is the Original Medicare answer. A Medicare Advantage plan administers the same Part B benefit but can layer its own prior-authorization and site-of-care rules on top — check the plan’s own policy rather than assuming the Original Medicare rules carry over.
The label gives two routes for every Injectafer dose: an undiluted slow IV push at about 100 mg per minute (a 750 mg dose runs about 7.5 minutes, billed 96374, $37.74), or dilution in up to 250 mL of 0.9% sodium chloride run over at least 15 minutes. CPT reports an infusion of 15 minutes or less as a push, so 96365 is only supportable when the documented infusion time exceeds 15 minutes — a 15-minute Injectafer infusion billed flat out as 96365, without that documented time, is the wrong code.
Payer citation language above is drawn from CareCost’s own ferric carboxymaltose policy corpus (16 payers, 181 rules). Check the specific payer’s language →
It depends on the payer and plan. 14 of the 16 ferric carboxymaltose policies CareCost has read require prior authorization before Injectafer is covered. Two payers — Arkansas BCBS and Independence Blue Cross — carry no formal prior-authorization rule; Independence still applies coverage criteria before it pays. Check this patient’s payer →
Not the bare D50 or the bare I50.2, I50.3 or I50.4. Iron-deficiency anemia without CKD bills to a fourth-character child of D50 — D50.9 is the code this site uses as the reference patient. The CKD indication pairs D63.1 with the CKD staging code. The heart-failure indication pairs E61.1 with a billable I50 child code such as I50.22 — never the bare I50.2 category code. Check the diagnosis coding →
It clusters on two numbers. BCBS Kansas, BCBS Minnesota and Capital BlueCross cap the standard course at 1,500 billable units (mg) per 35 days. Aetna and Excellus cap the single-dose alternative at 1,000 mg per course. For the heart-failure indication, BCBS Kansas and Capital BlueCross renew authorization in 12-week blocks up to a total of 3 maintenance doses. See the quantity-limit detail →
Oral-iron failure or intolerance, first: 15 of the 16 payers CareCost has read write it into a rule. Then, for 11 of the 16, documented failure of another IV iron — two of them, UnitedHealthcare and Independence Blue Cross, want failure on two separate products. Ten payers also name a ferritin threshold and seven a transferrin saturation (TSAT) threshold. No payer in this corpus asks for a serum phosphate level — that check is on the label, not in a payer’s policy. Open patient clearance →
Data current: payer policies Aug 2026 · reviewed dates come from each payer
Payer medical and pharmacy policies · prior-authorization criteria · clinical coverage criteria. ICD-10 codes verified against the NLM Clinical Table Search Service. Medicare coverage and fee-schedule amounts from the CMS Medicare Coverage Database and the Medicare Physician Fee Schedule. Every CareCost requirement links back to its source policy.